Daily cocaine self-administration under long-access conditions augments restraint-induced increases in plasma corticosterone and impairs glucocorticoid receptor-mediated negative feedback in rats.
Cocaine addiction appears to be associated with a drug-induced dysregulation of stressor responsiveness that may contribute to further cocaine use. The present study examined alterations in stressor-induced activation of the hypothalamic-pituitary-adrenal (HPA) axis in rats provided daily access to cocaine for self-administration (SA) under long-access conditions (1.0 mg/kg/infusion; 6 hx14 days). Cocaine self-administering rats displayed reduced basal plasma corticosterone (CORT) levels but showed an augmented restraint-induced percent increase response from baseline compared to saline self-administering controls when measured 24 days after SA testing. This augmented CORT response may have been attributable to impaired glucocorticoid receptor (GR)-mediated feedback regulation of HPA function, since cocaine self-administering rats were also less susceptible to dexamethasone (0.01 mg/kg, i.p.) suppression of plasma CORT levels. GR protein expression measured using Western blot analysis was significantly reduced in the dorsomedial hypothalamus (including the paraventricular nucleus [PVN]) but not in the pituitary gland, ventromedial hypothalamus, dorsal hippocampus, ventral subiculum, medial prefrontal cortex or amygdala in cocaine self-administering rats. Surprisingly, basal corticotropin-releasing hormone (CRH) mRNA or post-restraint increases in CRH mRNA measured at a single (90 min) time-point in the PVN using in situ hybridization did not differ between groups. The findings suggest that cocaine use produces persistent changes in individual responsiveness to stressors that may contribute to the addiction process.
Mantsch
John R
JR
Department of Biomedical Sciences, Box 1881, Marquette University, Milwaukee, WI 53201-1881, USA. john.mantsch@marquette.edu
Cullinan
William E
WE
Tang
Lee C
LC
Baker
David A
DA
Katz
Eric S
ES
Hoks
Michael A
MA
Ziegler
Dana R
DR
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D002908:Chronic Disease; D003042:Cocaine / Q000009:adverse effects; D019970:Cocaine-Related Disorders / Q000097:blood* / Q000503:physiopathology*; D003345:Corticosterone / Q000097:blood* / Q000378:metabolism; D003346:Corticotropin-Releasing Hormone / Q000235:genetics; D018765:Dopamine Uptake Inhibitors / Q000009:adverse effects; D004334:Drug Administration Schedule; D025461:Feedback, Physiological / Q000187:drug effects / Q000502:physiology; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D010913:Pituitary-Adrenal System / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D012333:RNA, Messenger / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011965:Receptors, Glucocorticoid / Q000187:drug effects* / Q000378:metabolism; D012149:Restraint, Physical / Q000009:adverse effects; D012646:Self Administration; D013315:Stress, Psychological / Q000097:blood* / Q000503:physiopathology*; D013995:Time
D018765:Dopamine Uptake Inhibitors; D012333:RNA, Messenger; D011965:Receptors, Glucocorticoid; D003346:Corticotropin-Releasing Hormone; D003042:Cocaine; D003345:Corticosterone
Eur J Pharmacol. 2000 Jan 3;387(1):59-62
10633161
Behav Pharmacol. 1999 Sep;10(5):523-9
10780258
J Pharmacol Exp Ther. 2000 Jul;294(1):239-47
10871318
Psychopharmacology (Berl). 2001 Mar;154(3):311-8
11351938
Psychoneuroendocrinology. 2002 Jan-Feb;27(1-2):71-82
11750770
Psychoneuroendocrinology. 2002 Jan-Feb;27(1-2):83-97
11750771
Psychopharmacology (Berl). 2001 Dec;158(4):343-59
11797055
Psychopharmacology (Berl). 2001 Dec;158(4):374-81
11797058
Neuropsychopharmacology. 2002 Mar;26(3):286-94
11850143
J Pharmacol Exp Ther. 2002 Jun;301(3):785-9
12023504
Brain Res. 2003 Feb 28;964(2):187-99
12576179
Psychopharmacology (Berl). 2003 Jul;168(1-2):177-83
12652344
Psychopharmacology (Berl). 2003 Jul;168(1-2):170-6
12845419
Psychoneuroendocrinology. 2003 Oct;28(7):836-62
12892653
Neuroendocrinology. 2003 Sep;78(3):154-62
14512708
Psychopharmacol Bull. 2003 Summer;37(3):84-9
14608241
Psychopharmacology (Berl). 2004 Aug;175(1):26-36
15042275
Endocrinology. 1965 Aug;77(2):406-8
4284417
Nature. 1970 Aug 15;227(5259):680-5
5432063
Proc Natl Acad Sci U S A. 1983 Nov;80(22):6982-6
6316340
Am J Physiol. 1985 Nov;249(5 Pt 2):R527-32
2998210
Brain Res. 1987 Oct 6;422(2):403-6
2823980
Peptides. 1987 Sep-Oct;8(5):819-22
2829143
Am J Psychiatry. 1988 Sep;145(9):1094-8
3414852
Anal Biochem. 1988 Nov 15;175(1):231-7
3245570
Brain Res. 1991 Mar 15;543(2):301-6
1647834
Mol Endocrinol. 1992 Jul;6(7):1061-9
1324419
Life Sci. 1992;51(12):887-97
1325586
Brain Res. 1992 Aug 28;589(1):154-6
1330207
J Pharmacol Exp Ther. 1992 Nov;263(2):505-9
1331401
Horm Res. 1992;37(6):221-4
1338055
Psychopharmacology (Berl). 1994 Jan;113(3-4):547-54
7862874
Eur J Pharmacol. 1995 Oct 24;285(3):317-21
8575521
Biol Psychiatry. 1995 Dec 1;38(11):751-5
8580229
J Pharmacol Exp Ther. 1996 Apr;277(1):225-34
8613924
J Pharmacol Exp Ther. 1996 Sep;278(3):1195-200
8819502
J Pharmacol Exp Ther. 1996 Oct;279(1):351-8
8859013
Neuroendocrinology. 1996 Nov;64(5):337-48
8930934
J Pharmacol Exp Ther. 1997 Jun;281(3):1401-7
9190876
Brain Res. 1998 Mar 30;788(1-2):305-10
9555067
J Neurosci. 1998 Jul 15;18(14):5529-36
9651233
J Pharmacol Exp Ther. 1998 Oct;287(1):72-80
9765324
Science. 1998 Oct 9;282(5387):298-300
9765157
Neuroendocrinology. 1998 Nov;68(5):334-44
9822801
J Pharmacol Exp Ther. 1999 Jul;290(1):393-402
10381805
Psychoneuroendocrinology. 2005 Oct;30(9):880-91
15975729
Endocrinology. 2005 Dec;146(12):5587-95
16150912
Neuropsychopharmacology. 2006 Mar;31(3):563-71
16034440
Arch Gen Psychiatry. 2006 Mar;63(3):324-31
16520439
Psychopharmacology (Berl). 2006 Jul;187(1):60-7
16598453
Neuropsychopharmacology. 2007 Feb;32(2):367-76
16641943
Neurosci Lett. 2007 Mar 30;415(3):269-73
17293045